Skip to Content

ASCO GI 2025: Danish Study Highlights Efficacy and Safety of Single-Cycle Neoadjuvant Pembrolizumab for Localized dMMR Colon Cancer

Findings from the RESET-C study suggest that a single cycle of neoadjuvant pembrolizumab offers high efficacy and manageable safety for patients with localized dMMR colon cancer, as presented at the ASCO Gastrointestinal Cancers Symposium.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top